



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

SUNitinib (Sutent®) 37.5 mg



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Metastatic GIST after failure of IMatinib.
 Metastatic Renal Cell Carcinoma.
 Advanced Neuroendocrine Tumors.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 80; Plt \geq 100,000

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
SUNitinib	37.5 mg PO once daily	To be given with or without food.
To be given daily, as a continuous daily dose until disease progression or intolerable toxicity.		

Special instructions: - Avoid grapefruit And grapefruit juice.
- Avoid drugs that prolong the QT interval.
- Avoid concomitant use with strong CYP3A4 inducers (Anticonvulsants) And inhibitors.

Treatment Description:

Cycle	Date	SUNitinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for \geq 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No